

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative products for unmet medical needs in neurology and psychiatry.

Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious neurological and psychiatric conditions through innovative products and distinctive, valuable programs for patients and physicians. Collaboration with key constituencies, including physicians, patients and industry partners, facilitates innovation and ensures therapeutics and new product candidates fulfill important medical needs.

Jazz Pharmaceuticals has built its pipeline by expertly leveraging novel formulations and drug delivery technologies to advance known and/or well-characterized compounds. This lower-risk model enables the company to maintain its focus on patient care with the goal of improving product efficacy, reducing adverse side effects and increasing patient compliance relative to existing therapies.

Products & Pipeline

Jazz Pharmaceuticals' development portfolio also includes JZP-4, JZP-7, and JZP-8. JZP-4 is a controlled-release formulation of elpetrigine, a new chemical entity that combines two mechanisms known to work well in anti-epileptic drugs: it is both a sodium channel and calcium channel blocker. JZP-4 has completed human proof-of-concept studies in epilepsy and also has promise in bipolar disorder. JZP-7 is a once-daily transdermal gel of ropinirole for the treatment of restless legs syndrome. JZP-8 is an intranasal formulation of clonazepam for the treatment of acute repetitive seizures. Consistent with its commitment to addressing areas of unmet neurological and psychiatric need, the company is identifying and evaluating product candidates with the goal of providing innovative solutions to these patients in need.



XYREM[®]
(sodium oxybate) oral solution



LUVOX CR[®]
fluvoxamine maleate extended-release capsules

	Clinical Development	Marketed
	Cataplexy and Excessive Daytime Sleepiness in Narcolepsy	
	Obsessive Compulsive Disorder and Social Anxiety Disorder	
JZP-6	Fibromyalgia	Submitted
JZP-7	Restless Legs Syndrome Phase II	
JZP-8	Acute Repetitive Seizures Phase II	
JZP-4	Epilepsy/Bipolar Disorder Phase I	

Fast Facts

Founded: 2003

NASDAQ Symbol: JAZZ

Headquarters: Palo Alto, California

Employees: 220

2008 Revenues: \$68 million

Products

XYREM[®] (sodium oxybate) approved for the treatment of excessive daytime sleepiness and cataplexy, in patients with Narcolepsy.

LUVOX CR[®] (fluvoxamine maleate) Extended Release Capsules approved for the treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder.

Commercial Operations

Jazz Pharmaceuticals markets XYREM and LUVOX CR in the United States through its specialty sales force. UCB markets XYREM in Europe and Valeant Canada Ltd. markets XYREM in Canada.

Key Pipeline Products

JZP-6: Fibromyalgia

JZP-7: Restless Legs Syndrome

JZP-8: Acute Repetitive Seizures

JZP-4: Epilepsy & Bipolar Disorder

Analyst Coverage

Barclays Capital
Leerink Swann
Lazard Capital Markets
Jefferies & Company

Investor Relations Contact

Ph: +1-650-496-2800
investorinfo@jazzpharmaceuticals.com

Products



XYREM® (sodium oxybate) is the only FDA-approved therapy for the treatment of the two most common daytime symptoms of narcolepsy, excessive daytime sleepiness (EDS) and cataplexy. Narcolepsy is a chronic and debilitating neurological sleep disorder caused by the brain's inability to regulate sleep-wake cycles. Narcolepsy is estimated to affect 1 in 2,000 people in the U.S., but fewer than 85,000 are diagnosed.



LUVOX CR®, a selective serotonin reuptake inhibitor (SSRI), is approved for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD), two difficult-to-treat, underdiagnosed and undertreated anxiety disorders. SAD affects approximately 15 million American adults, and OCD affects approximately 2.2 million American adults.

Product Development Candidates

Jazz Pharmaceuticals' development-stage product candidates were selected based on a clear medical need, and each is advanced to the next phase of development only after passing rigorous proof-of-concept evaluation in early studies.

The company's most advanced agent in development is JZP-6 (sodium oxybate) for the treatment of fibromyalgia, a chronic pain condition affecting approximately 6-12 million Americans. Two phase III clinical trials of JZP-6 have been completed and the company anticipates submitting a New Drug Application to the U.S. Food and Drug Administration by the end of 2009.

Commitment

Jazz Pharmaceuticals has supported patient advocacy groups to further public education and to develop unique resources for patients and physicians, including diagnostic screening tools, disease education websites and a patient assistance program. The programs are intended to increase awareness and improve knowledge of often misunderstood conditions, such as narcolepsy, OCD and SAD, and to help ensure that patients receive accurate diagnosis and access to effective treatment. Jazz Pharmaceuticals also seeks direct feedback from physicians through occasional scientific and medical advisory board meetings and consults with key opinion leaders in neurology and psychiatry to gain valuable insight into important unmet medical needs.

Please visit Jazz Pharmaceuticals at www.jazzpharmaceuticals.com.

Management

Jazz Pharmaceuticals' management team has a proven track record of successfully developing and commercializing medical treatments that deliver results.

Bruce C. Cozadd
Chairman and CEO

Robert M. Myers
President

Kathryn E. Falberg
SVP, Chief Financial Officer

Carol A. Gamble
*SVP, General Counsel &
Corporate Secretary*

Janne L. T. Wissel
*SVP, Chief Regulatory Officer &
Chief Compliance Officer*

Michael DesJardin
SVP, Product Development

Mark G. Eller, Ph.D.
SVP, Research & Clinical Development

Diane R. Guinta, Ph.D.
VP, Clinical Research & Development

P.J. Honerkamp
VP, Deputy General Counsel

Edwin W. Luker
VP, Sales

Annette Madrid, MD
*VP, Clinical and Experimental Medicine &
Chief Medical Officer*

Heather McGaughey
VP, Human Resources

Joel M. Rothman
VP, Development Operations

Board of Directors

Samuel D. Colella
Versant Ventures

Bruce C. Cozadd
Jazz Pharmaceuticals

Bryan C. Cressey
Cressey & Company LP

Patrick Enright
Longitude Capital

Michael W. Michelson
Kohlberg Kravis Roberts & Co. L.P.

James C. Momtazee
Kohlberg Kravis Roberts & Co. L.P.

Robert M. Myers
Jazz Pharmaceuticals

Kenneth W. O'Keefe
Beecken Petty O'Keefe & Company

Alan M. Sebulsky
Apothecary Capital LLC

James B. Tananbaum, MD
Prospect Venture Partners

Nathaniel M. Zilkha
Kohlberg Kravis Roberts & Co. L.P.